A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 7, 2010, Pages 1524-1531

  Dimitrov, J D ^a,b,c   Roumenina, L T ^a,b,c   Plantier, J L ^d   Andre, S ^a,b,c   Saboulard, D ^e   Meslier, Y ^a,b,c   Planchais, C ^a,b,c   Jacquemin, M ^f   Saint Remy, J M ^f   Atanasov, B P ^g   Kaveri, S V ^a,b,c   Lacroix Desmazes, S ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITÉ LYON 1   (France)

^e University of Leuven ^*  (France)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g INSTITUTE OF ORGANIC CHEMISTRY   (Bulgaria)

Author keywords

Factor VIII; FVIII inhibitors; Hemophilia A; Inhibitory mechanism; Surface electrostatics

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE; IMMUNOGLOBULIN; PROTEIN BO2C11; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; ELECTRIC POTENTIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION;

ANTIBODIES, MONOCLONAL; BINDING SITES; EPITOPES; FACTOR VIII; HEMOPHILIA A; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; STATIC ELECTRICITY; VON WILLEBRAND FACTOR;

EID: 77955038474     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03878.x     Document Type: Article

References (35)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001, 344:1773-9.
2. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992, 339:594-8.
3. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998, 92:3983-96.
4. Lavigne-Lissalde G, Schved JF, Granier C, Villard S. Anti-factor VIII antibodies: a 2005 update. Thromb Haemost 2005, 94:760-9.
5. Kazatchkine MD, Sultan Y, Burton-Kee EJ, Mowbray JF. Circulating immune complexes containing anti-FVIII antibodies in multitransfused patients with haemophilia A. Clin Exp Immunol 1980, 39:315-20.
6. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for FVIII inhibition. J Biol Chem 1996, 271:27424-31.
7. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999, 5:1044-7.
8. Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Villard S, Pashov A, Stieltjes N, d'Oiron R, Saint-Remy JM, Hoebeke J, Kazatchkine MD, Reinbolt J, Mohanty D, Kaveri SV. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002, 346:662-7.
9. Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlinck K, Gilles JG, Vermylen J, Saint-Remy JM. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998, 92:496-506.
10. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007, 110:4234-42.
11. Spiegel PC, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001, 98:13-9.
12. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 1997, 272:18007-14.
13. Liu ML, Shen BW, Nakaya S, Pratt KP, Fujikawa K, Davie EW, Stoddard BL, Thompson AR. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000, 96:979-87.
14. Spiegel PC, Murphy P, Stoddard BL. Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities. J Biol Chem 2004, 279:53691-8.
15. Vlot AJ, Koppelman SJ, Meijers JCM, Damas C, van den Berg HM, Bouma BN, Sixma JJ, Willems GM. Kinetics of factor VIII-von Willebrand factor association. Blood 1996, 87:1809-16.
16. Ngo JC, Huang M, Roth DA, Furie BC, Furie B. Crystal Structure of Human Factor VIII: implications for the Formation of the Factor IXa-Factor VIIIa Complex. Structure 2008, 16:597-606.
17. Shen BW, Spiegel PC, Chang CH, Huh JW, Lee JS, Kim J, Kim YH, Stoddard BL. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008, 111:1240-7.
18. Atanasov BP, Mustafi D, Makinen MW. Protonation of the beta-lactam nitrogen is the trigger event in the catalytic action of class A beta-lactamases. Proc Natl Acad Sci USA 2000, 97:3160-5.
19. Roumenina LT, Kantardjiev AA, Atanasov BP, Waters P, Gadjeva M, Reid KB, Mantovani A, Kishore U, Kojouharova MS. Role of Ca2+ in the electrostatic stability and the functional activity of the globular domain of human C1q. Biochemistry 2005, 44:14097-109.
20. Kantardjiev AA, Atanasov BP. PHEPS: web-based pH-dependent Protein Electrostatics Server. Nucleic Acids Res 2006, 34:W43-7.
21. Kantardjiev AA, Atanasov BP. PHEMTO: protein pH-dependent electric moment tools. Nucleic Acids Res 2009, 37:W422-7.
22. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004, 25:1605-12.
23. Saboulard D, Dugas V, Jaber M, Broutin J, Souteyrand E, Sylvestre J, Delcourt M. High-throughput site-directed mutagenesis using oligonucleotides synthesized on DNA chips. BioTechniques 2005, 39:363-8.
24. Plantier JL, Rodriguez MH, Enjolras N, Attali O, Negrier C. A factor VIII minigene comprising the truncated intron I of factor IX highly improves the in vitro production of factor VIII. Thromb Haemost 2001, 86:596-603.
25. Roumenina L, Bureeva S, Kantardjiev A, Karlinsky D, Andia-Pravdivy JE, Sim R, Kaplun A, Popov M, Kishore U, Atanasov B. Complement C1q-target proteins recognition is inhibited by electric moment effectors. J Mol Recognit 2007, 20:405-15.
26. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999, 402:439-42.
27. Brock K, Talley K, Coley K, Kundrotas P, Alexov E. Optimization of electrostatic interactions in protein-protein complexes. Biophys J 2007, 93:3340-52.
28. Shima M. Characterization of factor VIII inhibitors. Int J Hematol 2006, 83:109-18.
29. Dimitrov JD, Roumenina LT, Andre S, Repesse Y, Atanasov BP, Jacquemin M, Saint-Remy JM, Bayry J, Kaveri SV, Lacroix-Desmazes S. Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Mol Immunol 2009, 47:290-7.
30. Lollar P, Parker CG, Tracy RP. Molecular characterization of commercial porcine factor VIII concentrate. Blood 1988, 71:137-43.
31. Owen WG, Wagner RH. Antihemophilic factor: separation of an active fragment following dissociation by salts or detergents. Thromb Diath Haemorrh 1972, 27:502-15.
32. Thuy LP, Brown JE, Baugh RF, Hougie C. Effects of succinylation and dodecyl, succinylation on bovine factor VIII/von Willebrand factor complex. Thromb Res 1980, 18:305-13.
33. Ananyeva NM, Lacroix-Desmazes S, Hauser CA, Shima M, Ovanesov MV, Khrenov AV, Saenko EL. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004, 15:109-24.
34. Vencesla A, Corral-Rodriguez MA, Baena M, Cornet M, Domenech M, Baiget M, Fuentes-Prior P, Tizzano EF. Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites. Blood 2008, 111:3468-78.
35. Pipe SW, Kaufman RJ. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem 1996, 271:25671-6.